Decrease in Pharma Business Drives Response Genetics' Q3 Revenues Down 10 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Driven by a downswing in revenues from its pharmaceutical clients, Response Genetics today said that third-quarter revenues dipped 10 percent year over year to $5.1 million.

Revenues for the three months ended Sept. 30 compare to $5.6 million for the third quarter a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genetic method to gauge age of ancient samples, genetic polymorphisms in mouse strain, and more.

Two Stanford professors are turning to the online game EteRNA to develop a new way to diagnose tuberculosis.

Lita Nelsen from the Massachusetts Institute of Technology's technology-transfer office is retiring after decades there.

After nine years, the Canadian government is loosening its restrictions on government scientists' ability to speak to the press and public.